期刊文献+

培美曲塞联合吉西他滨治疗晚期转移性乳腺癌的疗效 被引量:2

在线阅读 下载PDF
导出
摘要 目的探讨培美曲塞联合吉西他滨治疗蒽环类及紫衫类失败的晚期转移性乳腺癌的疗效及安全性,为晚期转移性乳腺癌的治疗提供新的思路和方法。方法对50例曾使用蒽环类及紫衫类药物治疗失败的晚期转移性乳腺癌患者采用培美曲塞联合吉西他滨化疗方案。吉西他滨1 000 mg.m-2,静脉注射,第1、8天;培美曲塞500 mg.m-2,静脉注射,第1天;同时补充叶酸及维生素B12支持,地塞米松预处理。每21 d为1周期,2周期后评价疗效。结果50例患者均可评价疗效,其中完全缓解(CR)1例,部分缓解(PR)11例,稳定(SD)9例,进展(PD)29例。治疗有效率(RR)24%,疾病控制率(DCR)42%。中位疾病进展时间(TTP)4.1个月,中位生存期(OS)11.7个月。主要不良反应为骨髓抑制,表现为可逆性的白细胞及血小板减少。结论培美曲塞联合吉西他滨治疗蒽环类及紫衫类失败的晚期转移性乳腺癌疗效确切,不良反应可耐受。
作者 芦珊
出处 《实用临床医学(江西)》 CAS 2012年第12期32-34,F0004,共4页 Practical Clinical Medicine
基金 江西省卫生厅科技计划(20113074)
  • 相关文献

参考文献7

  • 1Cohen M H,Johnson J R,Wang Y C. FDA drug approval summary:pemetrexed forinjection (Alimta)for the treatment of non-small cell lung cancer[J].Oncologist(The),2005,(06):363-368.
  • 2Spielmann M,Martin M,Namer M. Activity of pemetrexed (ALIMTA,Multitargeted Antifolate,LY231514)in metastatic breast cancer patients previously treated with an anthracycline and a taxane:an Interim Analysis[J].Clinical Breast Cancer,2001,(01):47-51.
  • 3Garin A,Manikhas A,Biakhov M. A phase Ⅱ study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer[J].Breast Cancer Research and Treatment,2008,(02):309-315.doi:10.1007/s10549-007-9722-5.
  • 4Ma C X,Steen P,Rowland K M. A phase Ⅱ trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer:an NCCTG study[J].Annals of Oncology,2006,(02):226-231.
  • 5仇金荣,卢凯华,王建,张梅玲.培美曲塞联合卡培他滨治疗晚期乳腺癌的近期疗效观察[J].临床和实验医学杂志,2008,7(12):69-70. 被引量:8
  • 6Oettle H,Richards D,Ramanathan R K. A phase Ⅲ trial of pemetrexedplus gemcitabine versus gemcitabine in patients with unresectableor metastatic pancreatic cancer[J].Annals of Oncology,2005,(10):1639-1645.
  • 7张玺炜,高洪元,储冬英,赵子仪.培美曲塞联合顺铂方案治疗蒽环类及紫杉类治疗失败的晚期转移性乳腺癌的初步研究[J].中国癌症杂志,2009,19(9):697-700. 被引量:20

二级参考文献14

  • 1姜丽娜,于世英,熊慧华,张孟贤.胸苷磷酸化酶在癌组织中表达的研究[J].中华肿瘤杂志,2004,26(5):297-299. 被引量:72
  • 2Boyle P,Ferlay J.Cancer incidence and mortality in Europe,2004[J].Annal Oncol,2005,16(3):481-488.
  • 3Kataja V,Castiglione M,on behalf of the ESMO Guidelines Working Group.Locally recurrent or metastatic breast cancer.ESMO clinical recommendations for diagnosis,treatment and follow-up[J].Annal Oncol,2008,19(2):9-11.
  • 4Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].Cancer J Clin,2005,55(2):74-108.
  • 5Spielmann M,Marlin M,Namer M,et al.Activity of pemetrexed (ALIMTA,multitargeted antifolate,LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane:an interim analysis[J].Clin Breast Cancer,2001,2(1):47-51.
  • 6Hanauske AR,Chen V,Paoletti P,et al.Pemetrexed disodium:a novel antifolate clinically active against multiple solid tumors[J].Oncologist,2001,6(4):363-373.
  • 7Vogelzang N J,Ruathoven JJ,Symanowski J,et al.Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma[J].J Clin Oncol,2003,21(14):2636-2644.
  • 8Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with nonsmall cell lung cancer previously treated with chemotherapy[J].J Clin Oncol,2004,22(9):1589-1597.
  • 9Scagliotti GV,Parikh P,yon Pawel J,et al.Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small cell lung cancer[J].J Clin Oncol,2008,26(21):3543-3551.
  • 10Paridaens R,Dirix L,Dumez H,et al.Phase Ⅰ/Ⅱ pharmacokinetic study of pemetrexed and epirubiein in patients with locally advanced or metastatic breast cancer[J].Clin Breast Cancer,2007,7(11):861-866.

共引文献25

同被引文献14

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部